Publicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (33)

2015

  1. Sensory gating deficits in the attenuated psychosis syndrome

    Schizophrenia Research, Vol. 161, Núm. 2-3, pp. 277-282

2008

  1. Differential clinical, structural and P300 parameters in schizophrenia patients resistant to conventional neuroleptics

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, Núm. 1, pp. 257-266

  2. Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin-1 beta gene (2q13)

    Genes, Brain and Behavior, Vol. 7, Núm. 7, pp. 796-801

2007

  1. Changes in cortical volume with olanzapine in chronic schizophrenia

    Pharmacopsychiatry, Vol. 40, Núm. 4, pp. 135-139

  2. Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder

    European Psychiatry, Vol. 22, Núm. 8, pp. 505-512

2006

  1. Dorsolateral prefrontal and superior temporal volume deficits in first-episode psychoses that evolve into schizophrenia

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 256, Núm. 2, pp. 106-111

2005

  1. Association between excessive frontal cerebrospinal fluid and illness duration in males but not in females with schizophrenia

    European Psychiatry, Vol. 20, Núm. 4, pp. 332-338

  2. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement

    Psychopharmacology, Vol. 178, Núm. 1, pp. 17-26

  3. Hypofrontality in men with first-episode psychosis

    British Journal of Psychiatry, Vol. 186, Núm. MAR., pp. 203-208

  4. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia

    Schizophrenia Research, Vol. 80, Núm. 1, pp. 61-71

  5. N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration

    Schizophrenia Research, Vol. 73, Núm. 2-3, pp. 209-219

  6. Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia

    International Clinical Psychopharmacology, Vol. 20, Núm. 1, pp. 13-18

  7. Prefrontal atrophy in first episodes of schizophrenia associated with limbic metabolic hyperactivity

    Journal of Psychiatric Research, Vol. 39, Núm. 2, pp. 117-127

  8. Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene

    NeuroImage, Vol. 27, Núm. 4, pp. 1002-1006

2004

  1. Direct association between orbitofrontal atrophy and the response of psychotic symptoms to olanzapine in schizophrenia

    International Clinical Psychopharmacology, Vol. 19, Núm. 4, pp. 221-228

  2. Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients

    Psychiatry Research - Neuroimaging, Vol. 131, Núm. 1, pp. 45-56

2003

  1. Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia

    Psychiatry Research - Neuroimaging, Vol. 124, Núm. 3, pp. 153-161

  2. Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia

    Psychiatry Research - Neuroimaging, Vol. 124, Núm. 3, pp. 163-175

  3. Cerebral metabolic patterns in chronic and recent-onset schizophrenia

    Psychiatry Research - Neuroimaging, Vol. 122, Núm. 2, pp. 125-135

  4. Cerebral metabolism and risperidone treatment in schizophrenia

    Schizophrenia Research, Vol. 60, Núm. 1, pp. 1-7